1-3 of 3
Christian Brandl
Close
Sort by
Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD
Journal: Blood
Blood (2016) 128 (22): 1589.
https://doi.org/10.1182/blood.V128.22.1589.1589
Published: 2016
Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Clinical Trials & Observations
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer
Journal: Blood
Blood (2012) 119 (26): 6226–6233.
https://doi.org/10.1182/blood-2012-01-400515
Published: 2012
Includes: Supplemental data
Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 4798.
https://doi.org/10.1182/blood.V114.22.4798.4798
Published: 2009